The BRAF mutation present in the two successfully reprogramed ATCs can be found in ∼55% of advanced thyroid cancers, most commonly a valine-to-glutamic acid substitution at residue 600 (p.V600E) (Santarpia et al., 2008). This evidence concerns the gene BRAF and thyroid cancer.